Literature DB >> 7572948

Use of multiple reporting sources for perinatal hepatitis B surveillance and follow-up.

R M Ikeda1, G S Birkhead, M K Flynn, S F Thompson, D L Morse.   

Abstract

The New York State Perinatal Hepatitis B Prevention Program was implemented in New York State (excluding New York City) as a surveillance and control program in 1988. This report describes and evaluates the program and provides data from 1991 regarding hepatitis B surface antigen (HBsAg)-positive mothers and their infants' subsequent hepatitis B vaccination. The program was created using multiple existing surveillance and data collection systems. Completeness of case-ascertainment was estimated by means of the Chandra Sekar-Deming method (J Am Stat Assoc 1949; 44:101-15). An audit of hospital medical records and follow-up by local health departments were used to validate reporting accuracy. Of 158,273 live births in 1991, 363 (0.2%) were born to confirmed HBsAg-positive mothers. Estimated completeness of case-ascertainment was 96%. Thirty-five percent of HBsAg-positive mothers did not report risk factors for hepatitis B, confirming the need for universal testing. Of the infants, 83% received hepatitis B immune globulin and three doses of vaccine within one year of birth. By using existing data collection systems, the program was established quickly, and start-up funding and training requirements were simplified. Multiple reporting increased case-ascertainment to almost 100%. The program effectively identifies and ensures prompt vaccination of infants born to HBsAg-positive mothers.

Entities:  

Mesh:

Year:  1995        PMID: 7572948     DOI: 10.1093/oxfordjournals.aje.a117708

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  1 in total

1.  Assessment of State Perinatal Hepatitis B Prevention Laws.

Authors:  Lindsay A Culp; Lisa Caucci; Nancy E Fenlon; Megan C Lindley; Noele P Nelson; Trudy V Murphy
Journal:  Am J Prev Med       Date:  2016-12       Impact factor: 5.043

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.